This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 7 Q&As
Facts about C-C motif chemokine 19.
Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes.
Human | |
---|---|
Gene Name: | CCL19 |
Uniprot: | Q99731 |
Entrez: | 6363 |
Belongs to: |
---|
intercrine beta (chemokine CC) family |
beta chemokine exodus-3; Beta-chemokine exodus-3; CC chemokine ligand 19; C-C motif chemokine 19; CCL19; chemokine (C-C motif) ligand 19; CKb11; EBI1-ligand chemokine; ELC; ELCMIP-3-beta; Epstein-Barr virus-induced molecule 1 ligand chemokine; exodus-3; Macrophage inflammatory protein 3 beta; macrophage inflammatory protein 3-beta; MGC34433; MIP3 beta; MIP-3 beta; MIP-3b; MIP3BCK beta-11; SCYA19EBI1 ligand chemokine; small inducible cytokine subfamily A (Cys-Cys), member 19; Small-inducible cytokine A19
Mass (kDA):
10.993 kDA
Human | |
---|---|
Location: | 9p13.3 |
Sequence: | 9; NC_000009.12 (34689570..34691276, complement) |
Expressed at high levels in the lymph nodes, thymus and appendix. Intermediate levels seen in colon and trachea, while low levels found in spleen, small intestine, lung, kidney and stomach.
Secreted.
The CCL19 Marker could be used for many purposes in biological research. It can be used to track the trafficking of naive T cells and may also be useful for developing vaccines. In this article, we'll discuss how CCL19 works and how it interacts with CCR7 to help guide DC-T cell interactions. Its role is described in the immune and molecular adjuvant potential is also discussed.
CCL19 Marker (also known as MIP-3b) is a molecule that can be produced by a variety cells. It binds with a specific protein called CCR7. This protein is expressed in myeloid cells and mature DCs as well as T cells and activated lymphocytes. CCL19 induces the CCR7 receptor.
CCL19 may be responsible for the trafficking of T-cell-based vaccines. It also helps in the priming, preparation, and production of antigen-specific cells. These are just some of the many uses for this marker. Its presence in blood can be a benefit in disease research, and development. Here are some examples of CCL19 applications. CCL19 can be used as a marker to track T cell activation by the antigen-presenting Cell (T-cell).
CCL19 has been implicated with lymphoid Neogenesis and chronic inflammation. CCL19 is expressed de novo when it is involved in neuroinflammatory conditions. It is also found in bone marrow macrophages, which connect the brain to the immune system. CCL19 has been linked to spinal cord injury and microglia produce it. These results indicate that CCL19 plays a crucial role in promoting T cell trafficking in the CNS.
CCL19 plays a role in the differentiation and proliferation of CD8+ CD8+ cells. It also promotes the formation functional cytotoxic cell-killing T cells. These T cells may aid in the clearance of intrahepatic HBV particles and infected cells. Researchers can use CCL19, a marker for this gene, to understand how this molecule contributes in clearing HBV. It is worth investigating the role of CCL19 within immune responses.
A variety of immune cells also express the chemokine CCR7, which is responsible for obesity. These cells are associated lymphoid homing, cell migration, and lymphoid homing. Mice lacking CCR7 show decreased insulin resistance and diet-induced obesity. Their energy consumption is higher than wild-type mice. Boster Bio's collaborators have recently found that CCR7 is crucial in the regulation of adipose-tissue inflammation.
CCR7 is used to direct CLL cells' migration into the LN. The cells use chemotactic routes for entry into the lymph node. These cells also cross-talk, to obtain trophic substances. CCR7 plays a crucial role in tumor growth. CCR7 is a key component in CLL cell behavior. The chemokine receptor is an important part of the immune system.
CCR7 not only promotes cell migration but also aids in differentiation of naive and pathogenic T cells into disease-causing effector cells. CCR7 could also play a key role in regulating the egress T and B cells to the LN. Its receptor is necessary for the induction of a response against pathogens. CCR7 isn't the only factor that controls this signaling pathway.
As the ability to target CCR7 has increased dramatically in pre-clinical models, the development of a novel drug to inhibit this molecule is now a key priority for the treatment of CLL. This therapy could represent the beginning of a new age in CLL treatments. Before a positive clinical trial can begin, there are many questions. These questions are still being answered, but it is possible that CCR7 targeted drugs could be an effective treatment option.
T cell trafficking by the afferent LV is critical for naive t cell activation. This trafficking is associated to immune surveillance, and may also have anti-inflammatory effect. It can also serve as an intermediary between activated and non-activated T cell populations. These effects will be discussed in detail below. This article will discuss more of the molecular mechanisms that control T cell trafficking.
CXCL12 promotes Chemotaxis through activating T cells via CCR7 Ligands, according to the authors. CXCL12 also promotes the migration naive t cells towards CCR7ligands. The authors found that CXCL12 is expressed at comparable levels in naive and memory T cells. Its role is still being investigated, but it could play an important part in the regulation of lymphocyte trafficking.
CCR7 is responsible for controlling T cell trafficking. It also regulates the production of antigen specific cytokines. T cells can migrate through lymphatic sinuses, and then enter the bloodstream via hot areas. The authors found that CD4+ cells in naive CD4+ mice entered the medullary sinuses via a CCR7 dependent route. They preferentially migrated towards the paracortical area.
We can identify the genetic factors that regulate T cell trafficking and develop therapeutic strategies to enhance or limit antigen-specific CD8 cells. This research has enormous potential! These treatments could be beneficial in the treatment and prevention of many diseases. In addition to treating infection, increasing CD8 T cells recruitment is crucial in the treatment of tumors and autoimmunity. Understanding T cell movement will allow us to find better ways to combat immune disease.
Duke University scientists have created a new vaccine against the virus. This vaccine triggers neutralizing antibodies within the immune system through a nanoparticle. It protects against a variety o coronavirus-related infections. The nanoparticle, which contains a small amount coronavirus, binds with cell receptors and triggers the immune response. The vaccine contains an adjuvant, a chemical booster. The vaccine's success in primate models makes it extremely relevant for human healthcare. The study findings were published in Nature.
This new technology has many potential applications. Its potential for use in virus vaccines is fueled by the ability to produce multiple strains simultaneously. Its recent innovations in the field of peptide synthesis, delivery, and immunogenicity make them a good candidate for such a role. The company is also expanding in other areas.
While adjuvants are crucial in the production process of virus vaccines they can also be a major hindrance in the product development process. Safety of adjuvants is a concern. Aluminum salts are one of the oldest adjuvants, but their mechanism of action is unknown. In addition, aluminum salts are not able to induce an effective immune response when combined with a non-replicating subunit vaccine.
Boster Bio's newly discovered compound could be an ideal molecular adjuvant in vaccines. Its ability inducing immunity in mucosal tissue, a critical point in entry for pathogens could be a major breakthrough within the field of vaccination. The potential of this compound is immense. It has tremendous potential to be used as a molecular adjuvant in the production of virus vaccines.
Many cells express the CCL19 gene and it is responsible for many different processes. It has been found that it is highly expressed by lymphoid tissue and hepatocytes. Below are the top uses of CCL19. These results show that the CCL19 genome has many applications. CCL19 gene in lymphoid tissues, hepatocytes, and hepatocytes is most useful for detecting the presence of tumors and assessing patient health.
PMID: 9013939 by Rossi D.L., et al. Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta.
PMID: 9153236 by Yoshida R., et al. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7.
*More publications can be found for each product on its corresponding product page